Published in:
13-05-2022 | Metastasis | Original Article
Frequency and therapeutic strategy for patients with ovarian metastasis from gastric cancer
Published in: Langenbeck's Archives of Surgery | Issue 6/2022
Login to get accessAbstract
Purpose
This study aimed to analyze the clinicopathological features and treatment outcomes of ovarian metastasis from gastric cancer.
Methods
This study included 155 female patients with unresectable advanced or recurrent gastric cancer at the Kochi Medical School between January 2007 and December 2021. A review of patients with ovarian metastasis was conducted, and their clinicopathological information and survival outcomes were compared with respect to ovarian metastasis.
Results
Fifteen patients were diagnosed with ovarian metastasis from gastric cancer with a median age of 54 years (range: 30–87 years) and an incidence of 9.7%. The median age of patients who developed ovarian metastasis was significantly lower those without ovarian metastasis (54 years vs. 71 years, P = 0.014). The median survival time (MST) for 15 patients with unresectable advanced gastric cancer who developed ovarian metastasis was 21.4 months (range: 0.2–41.4 months). The MST for 15 patients who underwent surgical resection and systemic drug treatment including chemotherapy to ovarian metastasis was significantly higher than those who received systemic drug treatment alone (28.1 months vs. 10.0 months; P = 0.021).
Conclusion
Ovarian metastasis was found in 9.7% of female patients with unresectable advanced or recurrent gastric cancer and in younger patients than in those without ovarian metastasis. Multidisciplinary treatment, including surgical resection and systemic drug treatment for ovarian metastasis from gastric cancer, may benefit selected patients.